Amr Ismail, MD
Critical Care Medicine · Conway, ARNPI 1326493099
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by GSK at 33.1% of the total. Reporting peaked in 2023 at $555 and has fallen 82.2% since, to $99 in 2025.
Across 53 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$344
- AstraZeneca$111
- Sanofi$100
- Olympus America Inc.$87
- Mallinckrodt Hospital Products Inc.$83
- Actelion Pharmaceuticals US, Inc.$65
- plus $250 from 10 others
What the payments were for
- Food & beverage$1,039100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 22 | $344 |
| AstraZeneca | 7 | $111 |
| Sanofi | 4 | $100 |
| Olympus America Inc. | 1 | $87 |
| Mallinckrodt Hospital Products Inc. | 3 | $83 |
| Actelion Pharmaceuticals US, Inc. | 3 | $65 |
| Mylan Specialty L.p. | 4 | $65 |
| Baxter Healthcare | 1 | $26 |
| Medtronic | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Antares Pharma, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $21 |
| Bayer | 1 | $21 |
| Lilly USA, LLC | 1 | $17 |
| Ambu Inc. | 1 | $16 |
| Exelixis Inc. | 1 | $12 |
How this compares
$1,039 in reported general payments places this provider in the 65th percentile of 30 critical care medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 520 | $381,864 |
| OfevNintedanib Esylate | 15 | $195,582 |
| Spiriva RespimatTiotropium Bromide | 72 | $42,334 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 64 | $40,029 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 60 | $31,003 |
| Spiriva HandihalerTiotropium Bromide | 31 | $24,058 |
| SymbicortBudesonide/Formoterol Fumarate | 64 | $17,132 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $15,258 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $11,701 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $11,561 |
| Advair HfaFluticasone Propion/Salmeterol | 32 | $11,180 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 60 | $7,122 |
| DuleraMometasone/Formoterol | 15 | $6,644 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 236 | $5,379 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $344 | $439,687655 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $21 | $249,616109 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $111 | $57,161128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 30 critical care medicine providers in Arkansas.
Other critical care medicine in Conway
- Nayneshkumar PatelHot Springs$10K
- Christopher JohnLittle Rock$8K
- Muthukumar RadhakrishnanFort Smith$7K
- Syed MustafaHot Springs$5K
- Megan RashidLittle Rock$3K
- Cidney HulettLittle Rock$2K
- Aashish NeupaneFort Smith$2K
- Jaydon PetersonHot Springs$2K
- Muhammad JaffarLittle Rock$1K
- Mohankumar DoraiswamyFort Smith$800
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.